Pharmacologic treatment of fibromyalgia

Current Pain and Headache Reports

Volumn 5, Issue 4, 2001, Pages 351-358

  Barkhuizen, André ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Fibromyalgia; Interstitial Cystitis; Irritable Bowel Syndrome; Myofascial Pain; Tramadol

Indexed keywords

ANALGESIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

FATIGUE; FIBROMYALGIA; HUMAN; MOOD DISORDER; REVIEW; SLEEP DISORDER;

ANALGESICS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; FATIGUE; FIBROMYALGIA; HUMANS; MOOD DISORDERS; SLEEP DISORDERS;

EID: 0035430161     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-001-0025-y     Document Type: Article

References (73)

1. Bennett RM, Burckhardt CS, Clark SR, et al.: Group treatment of fibromyalgia: a 6-month outpatient program. J Rheumatol 1996, 23:521–528.
2. Bennett RM: Multidisciplinary group programs to treat fibromyalgia patients. Rheum Dis Clin North Am 1996, 22:351–367. DOI: 10.1016/S0889-857X(05)70276-3
3. Russell IJ: Fibromyalgia syndrome: approaches to management. Bull Rheum Dis 1996, 45:1–4.
4. Bennett RM, Campbell SM, Burckhardt C, et al.: A multidisciplinary approach to fibromyalgia management. J Musculoskeletal Med 1991, 8:21–32.
5. Russell IJ, Kamin M, Bennett RM, et al.: Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000, 6:250–257. DOI: 10.1097/00124743-200010000-00003
6. Bennett RM, Clark SR, Walczyk J: A randomized double blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998, 104:227–231. DOI: 10.1016/S0002-9343(97)00351-3
7. Goldenberg D, Mayskiy M, Mossey C, et al.: A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996, 39:1852–1859. DOI: 10.1002/art.1780391111
8. Russell IJ, Michalek JE, Flechas JD, Abraham GE: Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study. J Rheumatol 1995, 22:953–958.
9. Wolfe F, Cathey MA, Hawley DJ: A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994, 23:255–259.
10. Jacobsen S, Danneskiold-Samsoe B, Anderson RB: S-adenosylmethionine in primary fibromyalgia: double-blind clinical evaluation. Scand J Rheumatol 1991, 20:294–302.
11. Russell IJ, Fletcher EM, Michalek JE, et al.: Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: a double-blind, placebo-controlled study. Arthritis Rheum 1991, 34:552–560. DOI: 10.1002/art.1780340507
12. Quimby LG, Gratwick GM, Whitney CD, Black SR: A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol 1989, 16:140–143.
13. Bennett RM, Gatter RA, Campbell SM, et al.: A comparison of cyclobenzaprine and placebo in the management of fibrositis: a double-blind controlled study. Arthritis Rheum 1988, 31:1535–1542. DOI: 10.1002/art.1780311210
14. Tavoni A, Vitali C, Bombardieri S, Pasero G: Evaluation of S-adenosyl-methionine in primary fibromyalgia: a doubleblind crossover study. Am J Med 1987, 83:107–110. DOI: 10.1016/0002-9343(87)90862-X
15. Carette S, McCain GA, Bell DA, Fam AG: Evaluation of amitriptyline in primary fibrositis: a double-blind, placebocontrolled study. Arthritis Rheum 1986, 29:655–659. DOI: 10.1002/art.1780290510
16. Goldenberg DL, Felson DT, Dinerman H: A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986, 29:1371–1377. DOI: 10.1002/art.1780291110
17. Arnold LM, Keck PE, Welge JA: Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000, 41:104–113. This is a timely review of antidepressant therapy in fibromyalgia outlining the use of these agents, yet also pointing out their shortcomings. DOI: 10.1176/appi.psy.41.2.104
18. Rossy LA, Buckelew SP, Dorr N, et al.: A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med 1999, 21:180–191. This analysis confirms clinical experience in fibromyalgia management, yet adds some scientific basis to recommendations on the relative role of pharmacologic and nonpharmacologic treatment approaches. DOI: 10.1007/BF02908299
19. Alarcon GS, Bradley LA: Advances in the treatment of fibromyalgia: current status and future directions. Am J Med Sci 1998, 315:397–404. DOI: 10.1097/00000441-199806000-00008
20. Wolfe F: Is tramadol “effective” in fibromyalgia? Implications for study design and clinical effectiveness. J Clin Rheum 2000, 6:237–238.
21. Wolfe F, Anderson J, Harkness D, et al.: A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997, 40:1560–1570. DOI: 10.1002/art.1780400904
22. Wolfe F, Zhao S, Lane N: Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients. Arthritis Rheum 2000, 43:378–385. DOI: 10.1002/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2
23. Leventhal LJ: Management of fibromyalgia. Ann Intern Med 1999, 131:850–858.
24. Wolfe F, Smythe HA, Yunus MB, et al.: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990, 33:160–172. DOI: 10.1002/art.1780330203
25. Bendtsen L, Norregaard J, Jensen R, Olesen J: Evidence of qualitatively altered nociception in patients with fibromyalgia. Arthritis Rheum 1997, 40:98–102. DOI: 10.1002/art.1780400114
26. Bennett RM: Emerging concepts in the neurobiology of chronic pain. Evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 1999, 74:385–398. This is a landmark article summarizing the current evidence to place fibromyalgia among the central pain states, although acknowledging the importance of peripheral pain generators. DOI: 10.4065/74.4.385
27. Clauw DJ: The pathogenesis of chronic pain and fatigue syndromes, with special reference to fibromyalgia. Med Hypotheses 1995, 44:369–378. DOI: 10.1016/0306-9877(95)90263-5
28. Kosek E, Ekholm J, Hansson P: Sensory dysfunction in fibromyalgia patients with implications for pathogenetic mechanisms. Pain 1996, 68:375–383. DOI: 10.1016/S0304-3959(96)03188-0
29. Kramis RC, Roberts WJ, Gillette RG: Non-nociceptive aspects of persistent musculoskeletal pain. J Orthop Sports Phys Ther 1996, 24:255–267.
30. Lorenz J, Grasedyck K, Bromm B: Middle and long latency somatosensory evoked potentials after painful laser stimulation in patients with fibromyalgia syndrome. Electroencephalogr Clin Neurophysiol 1995, 100:165–168.
31. Mountz JM, Bradley LA, Modell JG, et al.: Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995, 38:926–938. DOI: 10.1002/art.1780380708
32. Russell IJ, Orr MD, Littman B, et al.: Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994, 37:1593–1601. DOI: 10.1002/art.1780371106
33. Russell IJ: Advances in fibromyalgia: a possible role for central neurochemicals. Am J Med Sci 1998, 315:377–384. This is an important article summarizing the neurochemical basis of fibromyalgia, providing much-needed information that fibromyalgia is indeed a valid construct with objective neurochemical abnormalities. DOI: 10.1097/00000441-199806000-00006
34. Weigent DA, Bradley LA, Blalock JE, Alarcon GS: Current concepts in the pathophysiology of abnormal pain perception in fibromyalgia. Am J Med Sci 1998, 315:405–412. DOI: 10.1097/00000441-199806000-00009
35. Loeser JD, Melzack R: Pain: an overview. Lancet 1999, 353:1607–1609. DOI: 10.1016/S0140-6736(99)01311-2
36. Bennett RM: Trigger point injections: what evidence for efficacy? J Musculoskeletal Med 1995, 12:11–12.
37. Borg-Stein J, Stein J: Trigger points and tender points. One and the same? Does injection treatment help? Rheum Dis Clin North Am 1996, 22:305–322. DOI: 10.1016/S0889-857X(05)70274-X
38. Frost FA, Jessen B, Siggaard-Andersen J: A control, doubleblind comparison of mepivacaine injection versus saline injection for myofascial pain. Lancet 1980, 1:499–501. DOI: 10.1016/S0140-6736(80)92761-0
39. Garvey TA, Marks MR, Wiesel SW: A prospective, randomized, double-blind evaluation of trigger point injection therapy for low-back pain. Spine 1989, 14:962–964. DOI: 10.1097/00007632-198909000-00008
40. Hamerhoff SR, Crago BR, Blitt CD, et al.: Comparison of bupivacaine, etidocaine, and saline for trigger-point therapy. Anesth Analg 1981, 60:752–755.
41. Hong C-Z: Lidocaine injection versus dry needling to myofascial trigger point. The importance of the local twitch response. Am J Phys Med Rehabil 1994, 73:256–263. DOI: 10.1097/00002060-199407000-00006
42. Hong C-Z, Hsueh T-C: Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil 1996, 77:1161–1166. DOI: 10.1016/S0003-9993(96)90141-0
43. Wreje U, Brorsson B: A multicenter randomized controlled trial of injections of sterile water and saline for chronic myofascial pain syndromes. Pain 1995, 61:441–444. DOI: 10.1016/0304-3959(94)00205-S
44. Fine PG, Milano R, Hare BD: The effects of myofascial trigger point injections are naloxone reversible. Pain 1988, 32:15–20. DOI: 10.1016/0304-3959(88)90018-8
45. Melzack R: Myofascial trigger points: relation to acupuncture and mechanisms of pain. Arch Phys Med Rehabil 1981, 628:114–117.
46. Cicero TJ, Adams EH, Geller A, et al.: A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend 1999, 57:7–22. DOI: 10.1016/S0376-8716(99)00041-1
47. Petrone D, Kamin M, Olson W: Slowing the titration rate of tramadol hydrochloride reduces the incidence of discontinuation due to nausea and/or vomiting: a double-blind randomized trial. J Clin Pharm Ther 1999, 24:115–123. DOI: 10.1046/j.1365-2710.1999.00203.x
48. Gasse C, Derby L, Vasilakis-Scaramozza C, Jick H: Incidence of first-time idiopathic seizures in users of tramadol. Pharmacotherapy 2000, 20:629–634. DOI: 10.1592/phco.20.7.629.35174
49. Sorensen J, Bengtsson A, Backman E, et al.: Pain analysis in patients with fibromyalgia: effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 1995, 24:360–365.
50. Graven-Nielsen T, Kendall SA, Henriksson KG, et al.: Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000, 85:483–491. This paper provides important information on a link between peripheral and central components of fibromyalgia, which ultimately may lead to new therapies. DOI: 10.1016/S0304-3959(99)00308-5
51. Clark SR, Bennett RM: Supplemental dextromethorphan in the treatment of fibromyalgia: a double-blind, placebocontrolled study of efficacy and side-effects. Arthritis Rheum 2000, 43(suppl 9):333.
52. Hrycaj P, Stratz T, Mennet P, Muller W: Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome - a preliminary study. J Rheumatol 1996, 23:1418–1423.
53. Carette S, Bell MY, Reynolds WJ, et al.: Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum 1994, 37:32–40. DOI: 10.1002/art.1780370106
54. Jung AC, Staiger T, Sullivan M: The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J Gen Intern Med 1997, 12:384–389. DOI: 10.1007/s11606-006-5088-3
55. Cote KA, Moldofsky H: Sleep, daytime symptoms, and cognitive performance in patients with fibromyalgia. J Rheumatol 1997, 24:2014–2023.
56. Drewes AM, Nielsen KD, Taagholt SJ, et al.: Sleep intensity in fibromyalgia: focus on the microstructure of the sleep process. Br J Rheumatol 1995, 34:629–635. DOI: 10.1093/rheumatology/34.7.629
57. Moldofsky H, Scarisbrick P, England R, Smythe H: Musculoskeletal symptoms and non-REM sleep disturbances in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med 1975, 37:341–351.
58. Moldofsky H, Scarisbrick P: Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med 1976, 38:35–44.
59. Moldofsky H: Sleep and musculoskeletal pain. Am J Med 1986, 81(suppl 3A):85–89. DOI: 10.1016/0002-9343(86)90883-1
60. Yunus MB, Aldag JC: Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ 1996, 312:1339.
61. Simon GE, VonKorff M: Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997, 154:1417–1423.
62. Moldofsky H, Lue FA, Mously C, et al.: The effect of zolpidem in patients with fibromyalgia: a dose ranging, double-blind, placebo controlled, modified crossover study. J Rheumatol 1996, 23:529–533.
63. Carette S: What have clinical trials taught us about the treatment of fibromyalgia? J Musculoskeletal Pain 1995, 3:133–140. DOI: 10.1300/J094v03n02_19
64. Goldenberg DL: Treatment of fibromyalgia syndrome. Rheum Dis Clin North Am 1989, 15:61–71.
65. Coward DM: Tizanidine: neuropharmacology and mechanisms of action. Neurology 1994, 44(suppl 9):S6–10.
66. Kaplan PW, Allen RP, Bucholz DW, Walters JK: A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993, 16:717–723.
67. Becker PM, Jamieson AO, Brown WD: Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: response and complications of extended treatment in 49 cases. Sleep 1993, 16:713–716.
68. Aaron LA, Bradley LA, Alarcon GS, et al.: Psychiatric diagnoses in patients with fibromyalgia are related to health careseeking behavior rather than to illness. Arthritis Rheum 1996, 39:436–445. DOI: 10.1002/art.1780390311
69. Ahles TA, Yunus MB, Riley SD, et al.: Psychological factors associated with primary fibromyalgia syndrome. Arthritis Rheum 1984, 27:1101–1106. DOI: 10.1002/art.1780271004
70. Goldenberg DL: Psychologic studies in fibrositis. Am J Med 1986, 81(suppl 3A):67–70. DOI: 10.1016/0002-9343(86)90879-X
71. Gruber AJ, Hudson JI, Pope HG: The management of treatment resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric syndrome. Psychiatr Clin North Am 1996, 19:351–369. DOI: 10.1016/S0193-953X(05)70292-6
72. Hudson JI, Goldenberg DL, Pope Harrington G, et al.: Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992, 92:363–367. DOI: 10.1016/0002-9343(92)90265-D
73. Norregaard J, Volkmann H, Danneskiold-Samsoe B: A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995, 61:445–449. DOI: 10.1016/0304-3959(94)00218-4